Leinco Technologies

Anti-Mouse IFNβ - Purified

Product Code:
 
LEI-I-440
Product Group:
 
Primary Antibodies
Host Type:
 
Hamster
Antibody Isotype:
 
IgG
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
MIB-5E9.1
Regulatory Status:
 
RUO
Target Species:
 
Mouse
Applications:
  • Neutralisation
  • Western Blot (WB)
Shipping:
 
Ambient
Storage:
 
This purified antibody is stable when stored at 2-8°C. Do not freeze.
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-I-440-50ug50 ug£148.00
Quantity:
LEI-I-440-500ug500 ug£262.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Show All

Further Information

Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified
Format:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Long Description:
Interferons (IFN) consist of two classes. The type I IFN class consists of 20 highly similar IFN-α proteins and a single IFN-β protein. The second class, type II IFN, consists of a single protein, IFN-γ. IFN-α and IFN-β signal through the same cell surface receptor IFNAR1 and have a similar range of biological activities including antiviral and antiproliferative activity. The type I IFNs also influence activation, growth and differentiation of T cells, B cells, macrophages, NK cells and other cell types such as endothelial cells and fibroblasts. IFN-β has recently proven to be beneficial in patients with multiple sclerosis and could also be a potential therapy for rheumatoid arthritis. It is unclear what cellular mechanisms are involved in IFN-β?s therapeutic effects, but they may be caused by a restoration of balance between pro- and anti-inflammatory cytokines.
Target:
IFNβ